Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 2 Device Recall IMMULITE 2000/2500 Chemiluminescent Substrate

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
  Class 2 Device Recall IMMULITE 2000/2500 Chemiluminescent Substrate see related information
Date Initiated by Firm May 15, 2009
Date Posted June 24, 2010
Recall Status1 Terminated 3 on January 18, 2011
Recall Number Z-1891-2010
Recall Event ID 52206
510(K)Number K970227  
Product Classification Discrete Photometric Chemistry Analyzer For Clinical Use - Product Code JJE
Product IMMULITE 2000/2500 Chemiluminescent Substrate Module

For the use in the routine operation of the IMMULITE 2000 and IMMULITE 2500 Analyzer.
Code Information Substrate lot L2SUBX 253 packed into Module L2SUBM 282 (EXP: 2010-07-31); Substrate lot L2SUBX 254 packed into Module L2SUBM 283 (EXP:2010-07-31); Substrate lot L2SUBX 255 packed into Module L2SUBM 284 (EXP: 2010-07-31); Substrate lot L2SUBX 256A packed into Module L2SUBM 288 (EXP:2010-08-31); Substrate lot L2SUBX 257A packed into Module L2SUBM 286 (EXP:2010-08-31); Substrate lot L2SUBX 258 packed into Module L2SUBM 285 (EXP: 2010-08-31); Substrate lot L2SUBX 259A packed into Module L2SUBM 287 (EXP: 2010-08-31).
Recalling Firm/
Manufacturer		 Siemens Healthcare Diagnostics Inc.
5700 W 96th St
Los Angeles CA 90045-5544
For Additional Information Contact
310-645-8200
Manufacturer Reason
for Recall		 These substrate lots have shown a tendency to introduce a shift in both control and patient results with multiple methods.
FDA Determined
Cause 2		 Device Design
Action An Urgent Field Safety Notice dated May 2009 was sent to consignees of record for the previously mentioned lots. The Notice advised the following: These substrate lots have shown a tendency to introduce a shift in both control and patient results with multiple methods. Actions If you are using one of these lots with your instrument, please take the following actions: 1. Upon receipt of a non-affected substrate lot, discontinue using IMMULITE 2000/2500 Chemiluminescent Substrate. Prior to receiving a non-affected substrate lot, you can continue to use the affected substrate if you follow the Interim Procedure. 2. Discard all bottles of the affected Substrate lots remaining in your inventory once non-affected Substrate lots are available. 3. The first time ONLY that you switch from one of the affected substrate lots in Table 1 to a non-affected lot, you should follow the procedure and steps below during instrument Startup: a. Empty the substrate reservoir completely before adding the new lot. b. Prime the instrument to cleanse the lines of the previous lot of substrate. c. Add the new lot of substrate to the reservoir and prime the instrument again.* d. Adjust all methods run on that instrument. *Note: Prime the substrate line as instructed on Page 83, Priming the Substrate Probe, of the IMMULITE 2000/2500 Operators Manual Rev. A. 4. Discuss the contents of this letter with your laboratory director. 5. Complete the Completion Notification Form that accompanies this notice and return it as directed on the form. Submitting this form indicates that you have received the information in the Urgent Field Safety Notice and have either discarded all lots of the affected IMMULITE 2000/2500 Substrate, or are following the Interim Procedure while awaiting the receipt of a non-affected Substrate lot and will discard the affected lots as soon as the non-affected lots are received in your laboratory. Interim Procedure Siemens recognizes that you
Quantity in Commerce 41,573
Distribution Nationwide Distribution
Total Product Life Cycle TPLC Device Report
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
510(K) Database 510(K)s with Product Code = JJE and Original Applicant = DPC CIRRUS
-
-